The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype-phenotype study
- PMID: 40691355
- DOI: 10.1007/s00535-025-02285-1
The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype-phenotype study
Abstract
Background: Increasing evidence reveals that immune cells significantly contribute to metabolic dysfunction-associated steatotic liver disease (MASLD) progression. The patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M variant has been linked to hepatic inflammation and fibrosis; however, its role in immune cell infiltration and activation within the liver remains unclear.
Methods: Seventy patients with MASLD were prospectively enrolled. Genomic DNA was extracted from buccal swabs or liver biopsy samples, followed by single nucleotide polymorphism genotyping to determine the rs738409 SNP genotype at codon 148 of PNPLA3. Immunohistochemistry was conducted using CD3 and CD68 antibodies to quantify T cell and macrophage infiltration, respectively. Total RNA extracted from biopsy specimens was used for quantitative reverse transcription polymerase chain reaction to assess the expression of specific markers associated with immune cell activation.
Results: Among the 70 patients with MASLD, 34 had the GG genotype, whereas 21 and 15 had the GC and CC genotypes, respectively. The GG genotype group showed a higher proportion of advanced fibrosis (F3 or F4) than the GC + CC group (P = 0.051). GG genotype carriers exhibited significantly higher CD3+ and CD68+ cell counts in the periportal region than the GC/CC carriers (P < 0.05). The transcriptomic analysis revealed elevated expression of markers associated with chronic antigen stimulation and immune cell activation (CD8A, GZMB, CCL2, and TIMP1) in GG carriers compared with those of GC and CC (P < 0.05). Furthermore, correlations among various markers, including inflammatory, steatosis-associated, and fibrosis-associated markers, exhibited consistent positive correlations.
Conclusions: Our findings revealed that the PNPLA3 I148M variant and increased immune cell infiltration and activation were significantly correlated within the MASLD liver. Further studies are needed to elucidate the mechanistic links between this genetic variant and liver inflammation.
Keywords: Immune cell; Liver fibrosis; Metabolic dysfunction-associated steatotic liver disease; PNPLA3.
© 2025. The Author(s), under exclusive licence to Japanese Society of Gastroenterology.
Conflict of interest statement
Declarations. Conflict of interests: The authors declare no conflicts of interest. Informed consent: Informed consent was obtained from all participants prior to the study enrolment. Institutional Review Board statement: This study was approved by the Institutional Review Board of the Catholic University of Korea (approval number: XC24TIDI0025). Informed consent was obtained from all participants prior to the study enrolment.
Similar articles
-
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants.JHEP Rep. 2024 Apr 6;6(7):101092. doi: 10.1016/j.jhepr.2024.101092. eCollection 2024 Jul. JHEP Rep. 2024. PMID: 39022386 Free PMC article.
-
PNPLA3 I148M variant links to adverse metabolic traits in MASLD during fasting and feeding.JHEP Rep. 2025 May 10;7(8):101450. doi: 10.1016/j.jhepr.2025.101450. eCollection 2025 Aug. JHEP Rep. 2025. PMID: 40677694 Free PMC article.
-
Global Epidemiology and Implications of PNPLA3 I148M Variant in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis.J Clin Exp Hepatol. 2025 May-Jun;15(3):102495. doi: 10.1016/j.jceh.2024.102495. Epub 2024 Dec 26. J Clin Exp Hepatol. 2025. PMID: 39882540 Review.
-
Polymorphism's MBOAT7 as Risk and MTARC1 as Protection for Liver Fibrosis in MASLD.Int J Mol Sci. 2025 Jul 3;26(13):6406. doi: 10.3390/ijms26136406. Int J Mol Sci. 2025. PMID: 40650184 Free PMC article.
-
PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.Liver Int. 2025 Mar;45(3):e16106. doi: 10.1111/liv.16106. Epub 2024 Nov 19. Liver Int. 2025. PMID: 39559944 Free PMC article. Review.
References
-
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. 2024;17:374–444.
-
- Esler WP, Cohen DE. Pharmacologic inhibition of lipogenesis for the treatment of NAFLD. J Hepatol. 2024;80:362–77. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous